JBAVX Performance — Balanced Fund, Class R5
Data updated: 2026-09-25
JBAVX returned +10.70% year to date and +19.63% over one year to Jul 2026. Annualised returns are +15.45% over 3 years and +8.84% over 5 years. The fund beat its Moderate Allocation category average: $100 invested three years ago grew to $154, against $138 for the category, and to $120 over one year, against $115. Volatility over the past three years was 9.27% a year. In the 12 months to Jul 2026 the fund took in a net $573.4M, and assets reached $6.92B.
JBAVX Growth of $100
What $100 invested in Balanced Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Moderate Allocation category average over the same months.
| Period | JBAVX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $120 | $115 |
| 3 years (Aug 2023 – Jul 2026) | $154 | $138 |
| 5 years (Aug 2021 – Jul 2026) | $153 | $133 |
| Since data start (Aug 2019 – Jul 2026) | $207 | $168 |
JBAVX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +10.70% |
| 1 year | +19.63% |
| 3 years (annualised) | +15.45% |
| 5 years (annualised) | +8.84% |
JBAVX Annual Returns
Calendar-year total returns of Balanced Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +10.70% |
| 2025 | +16.06% |
| 2024 | +13.67% |
| 2023 | +18.66% |
| 2022 | −15.46% |
| 2021 | +14.93% |
| 2020 | +16.41% |
| 2019 (Aug–Dec) | +5.37% |
JBAVX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.9% | +1.2% | −3.6% | +7.4% | +2.8% | +1.1% | −0.3% | — | — | — | — | — |
| 2025 | +3.2% | −1.0% | −3.9% | +0.4% | +3.5% | +4.3% | +0.9% | +1.5% | +2.6% | +2.2% | +2.0% | −0.5% |
| 2024 | +1.2% | +2.9% | +3.2% | −2.9% | +2.8% | +2.3% | +0.4% | +1.6% | +0.9% | −2.1% | +3.8% | −1.0% |
| 2023 | +4.7% | −3.2% | +3.5% | +1.4% | +0.2% | +3.4% | +2.3% | −0.8% | −3.7% | −1.2% | +6.7% | +4.6% |
| 2022 | −4.0% | −2.2% | +0.8% | −6.6% | +0.7% | −6.3% | +5.8% | −3.0% | −6.7% | +4.2% | +5.2% | −3.4% |
| 2021 | −0.2% | +1.0% | +1.4% | +3.7% | +0.9% | +1.6% | +1.5% | +2.4% | −3.1% | +2.9% | −0.8% | +2.9% |
| 2020 | +0.4% | −4.3% | −7.3% | +9.1% | +3.3% | +2.0% | +4.2% | +3.5% | −1.9% | −1.4% | +6.5% | +2.5% |
| 2019 | — | — | — | — | — | — | — | −0.5% | +0.9% | +1.3% | +2.0% | +1.6% |
JBAVX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 9.27%
- 3-year Sharpe ratio: 1.18 (vs 4.5% risk-free rate)
- Best month: +7.43% (Apr 2026)
- Worst month: −3.90% (Mar 2025)
JBAVX Fund Flows
Monthly money in and out of Balanced Fund, from SEC Form N-PORT.
- 12-month net flow: $573.4M
- 12-month gross sales (incl. reinvestments): $1.9B
- Sales ÷ redemptions: 1.43×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $95.1M | $99.8M | −$4.7M |
| Jun 2026 | $123.6M | $107.5M | $16.2M |
| May 2026 | $182.9M | $100.7M | $82.2M |
| Apr 2026 | $94.9M | $119.9M | −$25.0M |
| Mar 2026 | $111.4M | $117.2M | −$5.8M |
| Feb 2026 | $90.0M | $104.4M | −$14.4M |
| Jan 2026 | $94.4M | $116.6M | −$22.2M |
| Dec 2025 | $745.4M | $172.2M | $573.3M |
| Nov 2025 | $79.4M | $89.1M | −$9.8M |
| Oct 2025 | $101.5M | $106.5M | −$5.0M |
| Sep 2025 | $112.2M | $104.4M | $7.8M |
| Aug 2025 | $81.0M | $100.4M | −$19.3M |
JBAVX Assets Under Management
Net assets of Balanced Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $6.92B |
| 2026-04-30 | $6.62B |
| 2026-01-31 | $6.38B |
| 2025-10-31 | $6.27B |
| 2025-07-31 | $5.94B |
| 2025-04-30 | $5.50B |
| 2025-01-31 | $5.79B |
| 2024-10-31 | $5.45B |
| 2024-07-31 | $5.39B |
| 2024-04-30 | $5.01B |
| 2024-01-31 | $4.82B |
| 2023-10-31 | $4.22B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.